# **Opportunities of** collaboration with CIBER

### R&D&I & Tech-Transfer

- Open innovation
- Licensing out & Co-development projects
- Investment in Spin Off
- International projects (e.g.: H2020) •
- **R&D** Services .
- Clinical Trials & population studies .
- Patronage Opportunities (R&D projects, training actions, awareness campaigns, etc.)
- Others.

### **Training actions**

- Courses & Congresses
- Masters & PhD programs
- European projects (e.g.: ETNs)
- Clinical & Technological Training

### **Technology Platforms**

- NANBIOSIS ICTS (CIBER-BBN)
- **Bioinformatics Platform (CIBEREHD)**
- CIBERHEP. Chronic hepatitis B Platform (CIBEREHD) •
- e-CATCH (CIBEREHD)
- HEPA-C (CIBEREHD)
- REHEVASC. Register of Vascular Liver Diseases (CIBEREHD)
- Biobank Platform (CIBERER)
- **BIER (CIBERER)** .
- MAPER (CIBERER) .
- Pulmonary Biobank Consortium (CIBERES)
- ODS (CIBERESP) .
- **BIBLIOPRO (CIBERESP)** •
- FATBANK (CIBEROBN) •
- Mental Health & Disability Instruments Library Platform (CIBERSAM) •
- Neuroimaging Platform (CIBERSAM) •
- Data Base Common (CIBERSAM) •
- DNA Collection (CIBERSAM)

### Spin off

• Epidisease: epigenetic services & IVD developments www.epidisease.com



CIBER is the best network for the cooperative research in biomedicine in Spain

### "Together, we are better"

CONTACT Centro de Investigación Biomédica en Red (CIBER) Instituto de Salud Carlos III C/ Monforte de Lemos 3-5, Pab. 11, Pl. 0 - 28029 Madrid / SPAIN www.ciberisciii.es/en transferencia@ciberisciii.es

#### CIBER ISCIII





de Desarrollo Regional 'Una manera de hacer Europa"

### **CIBER** is a Spanish public consortium, whose main purpose is the promotion and protection of health through the development of research in different areas.

www.ciberisciii.es/en



## Thematic Areas

## Research programmes

<i>čiber-<mark>bb</mark>n</i>	Bioengineering, Biomaterials and Nanomedicine www.ciber-bbn.es/en	P1. Bioengineering and Medical Imaging P2. Biomaterials and Advanced Therapies P3. Nanomedicine	
<i>c</i> ibercv	Cardiovascular Diseases www.cibercv.es/en	<ul> <li>P1. Cardiac Damage and Associated Consequences</li> <li>P2. Arterial Disease, Myocardial Ischemia and Structural Damage</li> <li>P3. Cardiovascular Epidemiology and Risk Factors</li> <li>P4. Molecular and Imaging Biomarkers; Precision Cardiovascular Medicine</li> </ul>	
<i>c</i> ïber <mark>dem</mark>	Diabetes and associated Metabolic Diseases www.ciberdem.org/en	<ul> <li>P1. Epidemiology, Genetics and Epigenetics of Diabetes Mellitus. Chronic Complications and Comorbidities</li> <li>P2. Molecular and Cellular Determinants of Pancreatic Islets Function, Damage and Protection. Regenerative Medicine and Advanced Therapies</li> <li>P3. Cellular and Molecular Mechanisms Involved in the Development and Progression of Type 2 Diabetes and Identification of Novel Therapeutic Targets</li> </ul>	
<i>c</i> iberehd	Hepatic and Digestive Diseases www.ciberehd.org/en	<ul> <li>P1. Liver Damage Mechanisms/Evolution into Advanced Cirrhosis and Transplant</li> <li>P2. Gastrointestinal Physiopathology: Inflammatory Disease and Motility Disorders</li> <li>P3. Epidemiology, Prevention and Treatment of Hepatitis Virus Infection</li> <li>P4. Hepatic and Digestive Oncology</li> </ul>	
<i>c</i> iberer	Rare Diseases www.ciberer.es/en	P1. Genetic MedicineP5. Sensorineural PathologyP2. Inherited Metabolic MedicineP6. Endocrine MedicineP3. Mitochondrial and Neuromuscular MedicineP7. Inherited Cancer & Related SyndromesP4. Paediatric and Developmental MedicineP7. Inherited Cancer & Related Syndromes	
<i>c</i> iberes	Respiratory Diseases www.ciberes.org/en	<ul> <li>P1. Chronic Respiratory Diseases: Obstructive Sleep, Apnea, Asthma, Lung Cancer &amp; Chronic Obstructive Pulmonary Disease (COPD)</li> <li>P2. Infectious Respiratory Diseases: Host-Pathogen Interactions, Pneumonia &amp;Tuberculosis</li> <li>P3. Singular Respiratory Diseases: Pulmonary Fibrosis, Pulmonary Hypertension &amp; Acute Lung Injury (ALI)</li> </ul>	
<i>č</i> iberesp	Epidemiology and Public Health www.ciberesp.es/en	P2. Communicable Disease Prevention, Surveillance and Control (PREVICET)       P5. Ep         P3. Biological and Behavioural Determinants in the Contraction & Spread of       P6. He	ocial Determinants of Health oidemiology and Prevention in connection with Environmental and Occupational Health ealth Service Evaluation inical Epidemiology
<i>čiberfes</i>	Frailty and Healthy Aging www.ciberfes.es/en	P1. Basic, clinical and environmental mechanisms associated with the development of frailty P2. Tackling frailty. Detection, screening, diagnosis and treatment	
<i>c</i> iberobn	Phisiopathology of the Obesity and Nutrition www.ciberobn.es/en	P1. Nutrition P2. Obesity	About us The aim of the Centro de Investigación Biomédica en Red, CIBER, a public research consortium set up at the initiative of the
<i>c</i> iberonc	Cancer www.ciberonc.es/en	P1. Gastrointestinal TumoursP4. Haematological TumoursP2. Breast CancerP5. Low Prevalence TumoursP3. Respiratory Tract TumoursP6. Mechanisms of tumour progression	Instituto de Salud Carlos III (ISCIII) – belonging to the Ministry of Economy, Industry and Competitiviness (MINECO). Government of Spain)– is to further excellence research in Biomedicine and Health Sciences done in the National Health System and in the Science and Technology System.
<i>c</i> ibersam	Mental Health www.cibersam.es/en	P1. DepressionP4. Therapeutic InnovationP2. SchizophreniaP5. Mental Disorders of the Child and AdolescentP3. Bipolar DisorderP6. Psychosomatic, Anxiety and Impulse Control Disorders	To this end efforts and interdisciplinary and multi-institutional research are combined with a preferential dedication of financial resources around knowledge networks formed by centres and research groups reporting to different administrations and public and private institutions.